CMS To Stop Linking Payment For Aranesp, Procrit But Vows To Revisit Issue

CMS remains open to aligning the payment rate for Amgen's Aranesp with Johnson & Johnson's Procrit in future years, although for now the agency is acting on its proposal to retire the "equitable adjustment" method for reimbursing the drugs